Arcus biosciences announces new employment inducement grants

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the compensation committee of the company's board of directors granted fifteen new employees options to purchase a total of 49,650 shares of the company's common stock at an exercise price per share of $19.08, which was the closing price on may 23, 2022, and restricted stock units to acquire a total of 21,725
RCUS Ratings Summary
RCUS Quant Ranking